In this issue:
DCEP after novel agents for relapsed/refractory MM
Low uptake of upfront autologous SCT for MM
Bortezomib overcomes impact of renal impairment in newly diagnosed MM
Adding thalidomide to melphalan/prednisone prolongs MM survival
MGUS and risk of lymphoid/ myeloid malignancies
Post-transplant stringent CR important in MM
High-risk chromosomal aberrations predict smouldering MM progression
Prognostic significance of whole-body MRI in MGUS
Please login below to download this issue (PDF)